Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae.

Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae.

Show other versions (1)

Streptococcus pneumoniae (SPN) is a significant pathogen causing pneumonia and meningitis, particularly in vulnerable populations like children and the elderly. Available pneumonia vaccines have limitations since they only cover particular serotypes and have high production costs. The emergence of a...

Full description

Saved in:
Bibliographic Details
Main Authors: Md Nahian, Muhammad Shahab, Md Rasel Khan, Shopnil Akash, Tanjina Akhtar Banu, Murshed Hasan Sarkar, Barna Goswami, Sanjana Fatema Chowdhury, Mohammad Ariful Islam, Ahmed Abu Rus'd, Shamima Begum, Ahashan Habib, Aftab Ali Shaikh, Jonas Ivan Nobre Oliveira, Shahina Akter
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0317216
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Streptococcus pneumoniae (SPN) is a significant pathogen causing pneumonia and meningitis, particularly in vulnerable populations like children and the elderly. Available pneumonia vaccines have limitations since they only cover particular serotypes and have high production costs. The emergence of antibiotic-resistant SPN strains further underscores the need for a new, cost-effective, broad-spectrum vaccine. Two potential vaccine candidates, CbpA and PspA, were identified, and their B-cell, CTL, and HTL epitopes were predicted and connected with suitable linkers, adjivant and PADRE sequence. The vaccine construct was found to be antigenic, non-toxic, non-allergenic, and soluble. The three-dimensional structure of the vaccine candidate was built and validated. Docking analysis of the vaccine candidate by ClusPro demonstrated robust and stable binding interactions between the MEV and toll-like receptor 4 in both humans and animals. The iMOD server and Amber v.22 tool has verified the stability of the docking complexes. GenScript server confirmed the high efficiency of cloning for the construct and in-silico cloning into the pET28a (+) vector using SnapGene, demonstrating successful translation of the epitope region. Immunological responses were shown to be enhanced by the C-IMMSIM server. This study introduced a strong peptide vaccine candidate that has the potential to contribute to the development of a rapid and cost-effective solution for combating SPN. However, experimental verification is necessary to evaluate the vaccine's effectiveness.
ISSN:1932-6203

Similar Items